Summary: This webinar offers tips for incorporating elements of the successful COVID-19 vaccine rollout into future vaccine programs.

Summary: Catalent Biologics’ drug substance biomanufacturing services provide flexibility and scale to support your growth from clinical to commercial, with options to utilize single-use or stainless-steel bioreactors in a rigorous CGMP environment.

Summary: During this talk, we share the latest data leveraging GPEx Lightning to generate highly stable, highly productive cell pools and discuss how the GPEx suite of technologies can be tailored to the specific needs of each individual program on its path to clinical trials.

Summary: Dr. Mahdavi’s talk reviews key growth areas, innovative technologies and future strategies designed to increase the efficiency and scalability of advanced therapeutics.

Summary: In this webinar, leaders in the field discuss new vaccines and drugs that have resulted from COVID and key learnings to prepare for the next pandemic.

Summary: This roundtable discussion offers a closer look at oncology's hottest fields, including CAR-T and precision medicine, 2021's biggest research trends and the data they're most looking forward to seeing.

Summary: In this webinar executive summary, industry experts share diverse insights about challenges and opportunities with repurposing drugs for new disease treatments.

Summary: Experts discuss the changing experience from the last quarter of a century in the pathway to patients, and how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing.

Summary: Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors.

Summary: The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines.